Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on June 6, 2023. The filing serves as a Regulation FD disclosure regarding a presentation made by the company at the 13th Annual LD Micro Invitational in Los Angeles, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose the existence of an investor presentation (Exhibit 99.1) rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary event reported is the delivery of the investor presentation slides.
Guidance, Outlook, and Risks
The filing incorporates by reference the presentation slides dated June 6, 2023, which likely contain management commentary and outlook. However, the text of the 8-K itself does not summarize specific guidance, risks, or contingencies. It explicitly states that the information in this report, including the attached exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is Oncocyte Corporation (Ticker: OCX), not Insight Molecular Diagnostics Inc.
- Review Exhibit 99.1 (Investor Presentation) for actual financial data, strategic updates, and forward-looking statements.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act per the filing's disclaimer.
- Confirm the date of the event (June 6, 2023) aligns with the company's broader reporting calendar.